​
​

Sanofi (SNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SNY Stock Forecast

Sanofi stock forecast is as follows: an average price target of $57.36 (represents a 19.55% upside from SNY’s last price of $47.98) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

SNY Price Target

The average price target for Sanofi (SNY) is $57.36 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $64.00 to $48.07. This represents a potential 19.55% upside from SNY's last price of $47.98.

SNY Analyst Ratings

Buy

According to 7 Wall Street analysts, Sanofi's rating consensus is 'Buy'. The analyst rating breakdown for SNY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).

Sanofi Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2024Luisa HectorBerenberg Bank--9.38%33.39%
Jul 26, 2024Jasper HellwegArgus Research--14.21%25.05%
Apr 03, 2024Jasper HellwegArgus Research--14.58%14.63%
Dec 21, 2022Iain SimpsonBarclays---0.21%0.19%
Row per page
Go to

The latest Sanofi stock forecast, released on Sep 10, 2024 by Luisa Hector from Berenberg Bank, set a price target of $64.00, which represents a 9.38% increase from the stock price at the time of the forecast ($58.51), and a 33.39% increase from SNY last price ($47.98).

Sanofi Price Target by Period

1M3M12M
# Anlaysts-13
Avg Price Target-$64.00$59.67
Last Closing Price$47.98$47.98$47.98
Upside/Downside-100.00%33.39%24.36%

In the current month, the average price target of Sanofi stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sanofi's last price of $47.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2024Deutsche BankSellSellHold
Sep 23, 2024BarclaysOverweightOverweightHold
Sep 17, 2024CitigroupBuyBuyHold
Jul 29, 2024Deutsche BankSellSellHold
Jul 11, 2024GuggenheimBuyBuyHold
Jul 02, 2024JefferiesBuyBuyHold
Aug 18, 2022OppenheimerOutperformOutperformHold
Aug 12, 2022Deutsche BankHoldUpgrade
Jun 07, 2022UBSBuyBuyHold
Row per page
Go to

Sanofi's last stock rating was published by Deutsche Bank on Oct 10, 2024. The company gave SNY a "Sell" rating, the same as its previous rate.

Sanofi Financial Forecast

Sanofi Revenue Forecast

Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Jun 21Jun 20Mar 19Jun 18Mar 17Mar 16Sep 15Dec 13Sep 12Sep 11Dec 09Mar 08Mar 07Mar 06Mar 05
Revenue-------$10.86B$11.46B$10.05B$9.04B$8.44B$8.71B$8.48B$8.90B$7.93B$9.68B$8.54B$9.24B$9.17B$7.73B$7.09B$7.06B$7.32B$6.66B
Avg Forecast$11.67B$12.16B$13.15B$10.85B$10.62B$11.93B$12.48B$11.03B$12.73B$10.03B$10.54B$7.72B$8.02B$8.25B$8.26B$8.24B$9.46B$10.88B$12.08B$8.79B$10.50B$11.52B$5.76B$6.57B$6.15B
High Forecast$11.88B$12.80B$13.39B$11.04B$10.81B$12.33B$12.69B$13.24B$15.28B$12.03B$12.64B$9.27B$9.62B$9.89B$9.91B$9.88B$11.35B$13.06B$14.50B$10.55B$12.60B$13.83B$6.91B$7.89B$7.37B
Low Forecast$11.44B$11.35B$12.88B$10.62B$10.40B$11.58B$12.25B$8.82B$10.19B$8.02B$8.43B$6.18B$6.41B$6.60B$6.61B$6.59B$7.57B$8.71B$9.67B$7.03B$8.40B$9.22B$4.61B$5.26B$4.92B
# Analysts132223516209101614129121671712191713169
Surprise %-------0.98%0.90%1.00%0.86%1.09%1.09%1.03%1.08%0.96%1.02%0.79%0.76%1.04%0.74%0.62%1.23%1.11%1.08%

Sanofi's average Quarter revenue forecast for Sep 23 based on 5 analysts is $12.48B, with a low forecast of $12.25B, and a high forecast of $12.69B. SNY's average Quarter revenue forecast represents a 14.90% increase compared to the company's last Quarter revenue of $10.86B (Mar 23).

Sanofi EBITDA Forecast

Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Jun 21Jun 20Mar 19Jun 18Mar 17Mar 16Sep 15Dec 13Sep 12Sep 11Dec 09Mar 08Mar 07Mar 06Mar 05
# Analysts132223516209101614129121671712191713169
EBITDA-------$3.38B$2.71B$3.03B$1.99B$8.68B$2.06B$1.52B$6.65B$1.78B$2.63B$2.02B$3.00B$3.38B$2.29B$2.02B$1.33B$2.96B$2.09B
Avg Forecast$3.84B$4.00B$4.33B$3.57B$2.93B$3.93B$4.11B$2.66B$2.02B$2.42B$1.89B$2.60B$1.89B$1.48B$6.18B$1.85B$2.57B$2.58B$3.92B$3.25B$3.12B$3.28B$1.09B$2.66B$1.93B
High Forecast$3.91B$4.21B$4.41B$3.63B$3.51B$4.06B$4.18B$3.19B$2.42B$2.90B$2.26B$3.12B$2.27B$1.77B$7.41B$2.22B$3.08B$3.09B$4.70B$3.89B$3.74B$3.94B$1.30B$3.19B$2.32B
Low Forecast$3.76B$3.73B$4.24B$3.50B$2.34B$3.81B$4.03B$2.13B$1.62B$1.93B$1.51B$2.08B$1.51B$1.18B$4.94B$1.48B$2.05B$2.06B$3.14B$2.60B$2.49B$2.62B$869.91M$2.13B$1.54B
Surprise %-------1.27%1.34%1.25%1.05%3.34%1.09%1.03%1.08%0.96%1.02%0.79%0.76%1.04%0.74%0.62%1.23%1.11%1.08%

5 analysts predict SNY's average Quarter EBITDA for Sep 23 to be $4.11B, with a high of $4.18B and a low of $4.03B. This is 21.40% upper than Sanofi's previous annual EBITDA (Mar 23) of $3.38B.

Sanofi Net Income Forecast

Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Jun 21Jun 20Mar 19Jun 18Mar 17Mar 16Sep 15Dec 13Sep 12Sep 11Dec 09Mar 08Mar 07Mar 06Mar 05
# Analysts132223516209101614129121671712191713169
Net Income-------$2.00B$1.46B$2.01B$1.21B$7.60B$1.14B$762.00M$5.70B$1.09B$1.63B$1.06B$1.54B$2.03B$1.21B$1.17B$1.33B$1.51B$1.41B
Avg Forecast$1.26B$1.04B$1.57B$1.05B$2.04B$1.08B$1.64B$1.86B$1.19B$1.69B$1.15B$6.90B$1.05B$740.83M$5.29B$1.13B$1.59B$1.34B$2.01B$1.95B$1.64B$1.89B$1.09B$1.36B$1.31B
High Forecast$1.29B$1.12B$1.61B$1.07B$2.45B$1.22B$2.06B$2.23B$1.43B$2.03B$1.38B$8.28B$1.26B$889.00M$6.35B$1.36B$1.91B$1.61B$2.42B$2.34B$1.97B$2.27B$1.30B$1.63B$1.57B
Low Forecast$1.22B$957.46M$1.53B$1.02B$1.63B$1.03B$992.85M$1.49B$955.99M$1.35B$918.99M$5.52B$836.83M$592.67M$4.24B$903.48M$1.27B$1.08B$1.61B$1.56B$1.31B$1.52B$869.91M$1.09B$1.04B
Surprise %-------1.07%1.22%1.19%1.05%1.10%1.09%1.03%1.08%0.96%1.02%0.79%0.76%1.04%0.74%0.62%1.23%1.11%1.08%

Sanofi's average Quarter net income forecast for Sep 23 is $1.64B, with a range of $992.85M to $2.06B. SNY's average Quarter net income forecast represents a -17.90% decrease compared to the company's last Quarter net income of $2.00B (Mar 23).

Sanofi SG&A Forecast

Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Jun 21Jun 20Mar 19Jun 18Mar 17Mar 16Sep 15Dec 13Sep 12Sep 11Dec 09Mar 08Mar 07Mar 06Mar 05
# Analysts132223516209101614129121671712191713169
SG&A-------$2.61B$2.90B$2.38B$2.34B$2.27B$2.38B$2.51B$2.48B$2.21B$2.46B$2.15B$2.18B$2.11B$1.99B$1.78B---
Avg Forecast$2.86B$2.97B$3.22B$2.65B$2.42B$2.92B$3.05B$2.20B$2.91B$2.00B$2.22B$2.06B$2.19B$2.44B$2.30B$2.30B$2.41B$2.74B$2.85B$2.03B$2.71B$2.90B$1.42B$1.62B$1.52B
High Forecast$2.91B$3.13B$3.27B$2.70B$2.90B$3.02B$3.10B$2.64B$3.50B$2.40B$2.66B$2.47B$2.62B$2.92B$2.76B$2.76B$2.89B$3.28B$3.41B$2.43B$3.25B$3.47B$1.71B$1.95B$1.82B
Low Forecast$2.80B$2.77B$3.15B$2.60B$1.94B$2.83B$3.00B$1.76B$2.33B$1.60B$1.77B$1.64B$1.75B$1.95B$1.84B$1.84B$1.92B$2.19B$2.28B$1.62B$2.16B$2.32B$1.14B$1.30B$1.21B
Surprise %-------1.19%0.99%1.19%1.05%1.10%1.09%1.03%1.08%0.96%1.02%0.79%0.76%1.04%0.74%0.62%---

Sanofi's average Quarter SG&A projection for Sep 23 is $3.05B, based on 5 Wall Street analysts, with a range of $3.00B to $3.10B. The forecast indicates a 17.09% rise compared to SNY last annual SG&A of $2.61B (Mar 23).

Sanofi EPS Forecast

Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Jun 21Jun 20Mar 19Jun 18Mar 17Mar 16Sep 15Dec 13Sep 12Sep 11Dec 09Mar 08Mar 07Mar 06Mar 05
# Analysts132223516209101614129121671712191713169
EPS-------$0.80$0.58$0.81$0.48$3.03$0.46$0.31$2.26$0.42$0.63$0.40$0.58$0.76$0.46$0.44$0.49$0.56$0.53
Avg Forecast$1.00$0.82$1.25$0.83$0.86$0.86$1.30$0.80$0.74$0.71$0.63$0.52$0.61$0.60$0.61$0.70$0.77$1.23$1.95$0.86$1.95$5.61$0.53$0.65$0.46
High Forecast$1.02$0.89$1.28$0.85$0.88$0.97$1.64$0.97$0.90$0.86$0.76$0.63$0.74$0.72$0.73$0.84$0.92$1.48$2.33$1.03$2.34$6.73$0.64$0.79$0.56
Low Forecast$0.97$0.76$1.21$0.81$0.84$0.82$0.79$0.63$0.59$0.57$0.51$0.42$0.49$0.48$0.49$0.56$0.62$0.98$1.56$0.69$1.56$4.48$0.43$0.52$0.37
Surprise %-------1.00%0.78%1.14%0.77%5.79%0.74%0.51%3.73%0.60%0.81%0.33%0.30%0.88%0.24%0.08%0.93%0.86%1.14%

According to 5 Wall Street analysts, Sanofi's projected average Quarter EPS for Sep 23 is $1.30, with a low estimate of $0.79 and a high estimate of $1.64. This represents a 62.64% increase compared to SNY previous annual EPS of $0.80 (Mar 23).

Sanofi Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GSKGSK--72.11%Hold
AZNAstraZeneca--30.72%Buy
MRKMerck--29.07%Buy
SNYSanofi--19.55%Buy
JNJJohnson & Johnson--15.20%Buy
BMYBristol-Myers Squibb Company--12.48%Hold
NVSNovartis--12.02%Hold
AMGNAmgen--4.11%Buy
ABBVAbbVie--0.91%Buy
GILDGilead Sciences---8.90%Buy

SNY Forecast FAQ

Is Sanofi a good buy?

Yes, according to 7 Wall Street analysts, Sanofi (SNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of SNY's total ratings.

What is SNY's price target?

Sanofi (SNY) average price target is $57.36 with a range of $48.07 to $64, implying a 19.55% from its last price of $47.98. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sanofi stock go up soon?

According to Wall Street analysts' prediction for SNY stock, the company can go up by 19.55% (from the last price of $47.98 to the average price target of $57.36), up by 33.39% based on the highest stock price target, and up by 0.19% based on the lowest stock price target.

Can Sanofi stock reach $70?

SNY's average twelve months analyst stock price target of $57.36 does not support the claim that Sanofi can reach $70 in the near future.

What are Sanofi's analysts' financial forecasts?

Sanofi's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $35.44B (high $38.26B, low $32.66B), average EBITDA is $10.69B (high $11.43B, low $9.97B), average net income is $4.58B (high $5.51B, low $3.51B), average SG&A $8.17B (high $8.76B, low $7.59B), and average EPS is $2.96 (high $3.57, low $2.24). SNY's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $46.78B (high $48.04B, low $45.25B), average EBITDA is $14.83B (high $15.76B, low $13.81B), average net income is $5.7B (high $6.25B, low $5.14B), average SG&A $11.26B (high $12.01B, low $10.46B), and average EPS is $3.76 (high $3.9, low $3.62).

Did the SNY's actual financial results beat the analysts' financial forecasts?

Based on Sanofi's last annual report (Dec 2022), the company's revenue was $45.39B, beating the average analysts forecast of $22.76B by 99.44%. Apple's EBITDA was $13.77B, beating the average prediction of $4.44B by 210.21%. The company's net income was $6.72B, beating the average estimation of $2.88B by 133.06%. Apple's SG&A was $10.49B, beating the average forecast of $4.91B by 113.54%. Lastly, the company's EPS was $3.35, beating the average prediction of $1.46 by 129.92%. In terms of the last quarterly report (Mar 2023), Sanofi's revenue was $10.86B, missing the average analysts' forecast of $11.03B by -1.51%. The company's EBITDA was $3.38B, beating the average prediction of $2.66B by 27.15%. Sanofi's net income was $2B, beating the average estimation of $1.86B by 7.42%. The company's SG&A was $2.61B, beating the average forecast of $2.2B by 18.54%. Lastly, the company's EPS was $0.8, missing the average prediction of $0.8 by -0.00%